JP2017530950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530950A5 JP2017530950A5 JP2017511242A JP2017511242A JP2017530950A5 JP 2017530950 A5 JP2017530950 A5 JP 2017530950A5 JP 2017511242 A JP2017511242 A JP 2017511242A JP 2017511242 A JP2017511242 A JP 2017511242A JP 2017530950 A5 JP2017530950 A5 JP 2017530950A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lymphoma
- medicament
- cell
- alk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041288P | 2014-08-25 | 2014-08-25 | |
| US62/041,288 | 2014-08-25 | ||
| PCT/US2015/046477 WO2016032927A1 (en) | 2014-08-25 | 2015-08-24 | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067185A Division JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530950A JP2017530950A (ja) | 2017-10-19 |
| JP2017530950A5 true JP2017530950A5 (enExample) | 2018-09-20 |
Family
ID=54035336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511242A Withdrawn JP2017530950A (ja) | 2014-08-25 | 2015-08-24 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
| JP2020067185A Pending JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067185A Pending JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10695426B2 (enExample) |
| EP (1) | EP3185866A1 (enExample) |
| JP (2) | JP2017530950A (enExample) |
| CA (1) | CA2955676A1 (enExample) |
| WO (1) | WO2016032927A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| ES2783026T3 (es) | 2014-02-04 | 2020-09-16 | Pfizer | Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN108350081A (zh) * | 2015-11-18 | 2018-07-31 | 百时美施贵宝公司 | 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌 |
| WO2018027524A1 (en) | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| JP6928083B2 (ja) | 2016-09-15 | 2021-09-01 | レイドス， インコーポレイテッド | Ｐｄ−１ペプチド阻害剤 |
| WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| AU2017378782A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| EP3568204B1 (en) | 2017-01-10 | 2023-08-30 | Novartis AG | Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor |
| RU2765997C2 (ru) | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| CN111213059B (zh) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| JP2021513541A (ja) | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体によるがんの処置方法 |
| WO2019168524A1 (en) | 2018-02-27 | 2019-09-06 | Leidos, Inc. | Pd-1 peptide inhibitors |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3099547A1 (en) * | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| US20200030443A1 (en) | 2018-06-23 | 2020-01-30 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| US20200171146A1 (en) | 2018-07-18 | 2020-06-04 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3911678A1 (en) | 2019-01-14 | 2021-11-24 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
| MX2021012692A (es) | 2019-04-19 | 2021-11-12 | Genentech Inc | Anticuerpos anti-mertk y sus metodos de uso. |
| JP7606471B2 (ja) | 2019-05-22 | 2024-12-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| GB201915618D0 (en) * | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| CN114728905B (zh) | 2019-11-13 | 2025-08-01 | 基因泰克公司 | 治疗性化合物及使用方法 |
| KR20220136378A (ko) | 2020-01-31 | 2022-10-07 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법 |
| US11338040B2 (en) | 2020-06-04 | 2022-05-24 | Leidos, Inc. | Immunomodulatory compounds |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| WO2022063220A1 (en) * | 2020-09-25 | 2022-03-31 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
| JP2023548662A (ja) | 2020-10-12 | 2023-11-20 | レイドス， インコーポレイテッド | 免疫調節性ペプチド |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
| KR20230095113A (ko) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약 |
| AU2021374590A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| CA3202523A1 (en) | 2020-12-02 | 2022-06-09 | Genentech, Inc. | Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022232503A1 (en) | 2021-04-30 | 2022-11-03 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
| CA3223534A1 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| TW202320848A (zh) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
| KR20240038008A (ko) | 2021-07-28 | 2024-03-22 | 에프. 호프만-라 로슈 아게 | 암 치료 방법 및 조성물 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| EP4436969A2 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |
| EP4436957A1 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| EP4444303A4 (en) * | 2021-12-06 | 2025-11-26 | Ideaya Biosciences Inc | POLYTHERAPY INCLUDING A PKC INHIBITOR AND A C-MET INHIBITOR |
| WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| CN119317641A (zh) | 2022-05-11 | 2025-01-14 | 基因泰克公司 | 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| KR20250039386A (ko) | 2022-07-13 | 2025-03-20 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 |
| TW202413433A (zh) | 2022-07-19 | 2024-04-01 | 美商建南德克公司 | 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| CN120153254A (zh) | 2022-09-01 | 2025-06-13 | 基因泰克公司 | 膀胱癌的治疗和诊断方法 |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| KR20250122520A (ko) | 2022-12-20 | 2025-08-13 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법 |
| AU2024270495A1 (en) | 2023-05-05 | 2025-10-09 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| EP4709484A1 (en) | 2023-05-10 | 2026-03-18 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2024263195A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2024263904A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
| WO2025155607A1 (en) | 2024-01-16 | 2025-07-24 | Genentech, Inc. | Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| BRPI0409230A (pt) | 2003-04-03 | 2006-03-28 | Pfizer | formas de dosagem compreendendo ag013736 |
| ATE492544T1 (de) | 2004-08-26 | 2011-01-15 | Pfizer | Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer |
| GEP20104906B (en) | 2004-08-26 | 2010-02-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| JP2008518904A (ja) | 2004-11-02 | 2008-06-05 | ファイザー・インク | ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態 |
| KR20070058690A (ko) | 2004-11-02 | 2007-06-08 | 화이자 인코포레이티드 | 인다졸 화합물의 제조방법 |
| CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| RU2007114112A (ru) | 2004-11-02 | 2008-12-10 | Пфайзер Инк. (US) | Способ получения индазольных соединений |
| CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2608952A1 (en) | 2005-05-19 | 2006-11-23 | Dwayne Thomas Friesen | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| BRPI0619424B1 (pt) | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| KR101146852B1 (ko) | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| EP2140463B1 (en) | 2007-03-29 | 2017-05-31 | Cellutech AB | Magnetic nanoparticle cellulose material |
| EP4249063A3 (en) | 2007-04-05 | 2024-03-13 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| MX341076B (es) * | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| HK1198133A1 (en) | 2011-08-02 | 2015-03-13 | 辉瑞公司 | Crizotinib for use in the treatment of cancer |
| US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| CA2855211A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160084839A1 (en) * | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| AU2015210886A1 (en) * | 2014-01-29 | 2016-09-01 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| CA3000386A1 (en) * | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
-
2015
- 2015-08-24 CA CA2955676A patent/CA2955676A1/en not_active Abandoned
- 2015-08-24 JP JP2017511242A patent/JP2017530950A/ja not_active Withdrawn
- 2015-08-24 EP EP15757408.8A patent/EP3185866A1/en not_active Withdrawn
- 2015-08-24 US US15/506,316 patent/US10695426B2/en active Active
- 2015-08-24 WO PCT/US2015/046477 patent/WO2016032927A1/en not_active Ceased
-
2020
- 2020-04-03 JP JP2020067185A patent/JP2020117524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506227A5 (enExample) | ||
| JP2018512391A5 (enExample) | ||
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| Reck et al. | Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | |
| de Wit et al. | Individualized dosing of tyrosine kinase inhibitors: are we there yet? | |
| Landes et al. | The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| AU2018335617B2 (en) | Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer | |
| JP2019506403A5 (enExample) | ||
| JP2017537070A5 (enExample) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2017117664A (ru) | Комбинация | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| Burke et al. | An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma | |
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| JP2016533366A5 (enExample) | ||
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP2018524347A5 (enExample) | ||
| JP2018508516A5 (enExample) |